This document contains information on European and United States guidelines on the interchangeability of biosimilars. It includes studies where people switched from an insulin reference product to a biosimilar and advice on the use of biosimilars in clinical practice.
Using This Tool
The information contained here can be used to better understand the clinical impact of switching between reference and biosimilar insulins, as seen from the position of countries with experience in regulating biosimilars and with robust regulatory pathways.
Please help us improve our toolkit! This online toolkit is in its pilot phase and your feedback can help to greatly improve our tools. Please email us with your comments about specific tools, or provide suggestions about other tools we can add. Contact us at email@example.com.